SlideShare a Scribd company logo
Margie Morgan, PhD, MT(ASCP),
D(ABMM)
microbeswithmorgan.com
1.Direct Staining for Antigen
2. Enzyme Immunoassay
3. Molecular Amplification
4.Viral Cell Culture
 Direct Fluorescent antibody (DFA) stain
 Collect cells from base of fresh vesicular lesion
 Stain with Fl antibody specific for HSV and/or VZV
 Look for fluorescent cells (virus infected) using fluorescence
microscope
 More sensitive & specific method than Tzanck prep for
virus detection (DFA 80% vs. Tzanck 50%)
 Tzanck prep= Giemsa staining cells from lesion
-/examine for multinucleated giant cells of Herpes
virus
Tzanck
Tzanck
DFA
• Enzyme immunoassay (EIA) –
 Antigen/antibody complex formed – then bound to
a color producing substrate
 Used most often
 Detection of non-culturable viruses – Rotavirus
 Influenza A and B , & Respiratory syncytial virus (RSV)
from nasal/NP swab – point of care
• Membrane EIA Liquid/well EIA
 Molecular Amplification (DNA or RNA)
• Rapid/Sensitive/Specific for numerous viruses
• Exceeds sensitivity of culture/ new Gold standard
 Respiratory viruses
 HSV and Enterovirus detection from CSF
 Culture <=20% PCR >=90%
 Tests of diagnosis not cure – can shed residual virus for 7 –
30 days after initial positive test
• CMV - Quantitative assays in transplantation
• Hepatitis B and C detection and viral load
• HIV viral load
• Inner tube wall coated with monolayer of cells plus
liquid growth media
• Three types of cell lines:
 Primary cell lines – direct from animal or human organ
into culture tube subculture once
 Rhesus monkey kidney-RMK
 Diploid – semi continuous cell lines– Can survive 20 – 50
subcultures into new vials –
 Human diploid fibroblast cells, example: MRC-5-Microbiology
Research Council 5
 Continuous cell lines – can survive continuous passage
into new vials,
 Tumor lineage, HEp-2 and HeLa
 Patient specimens inoculated into cell culture
tubes, incubated, then read under light
microscopy for “Cytopathic effect” – the effect
the virus has on the cell monolayer
• The pattern of destruction is specific for each
virus type
Spin Down Shell Vial Culture –
•Speed up virus detection
•Cell monolayer on coverslip/vial
•Specimen inoculated into vial
•Centrifuge vial to induce virus invasion into cells
•Incubate @ 35C, 24-72 hours
•Direct fluorescent antibody stain of coverslip – target
early virus antigens (those first formed )
Cover slip
 Viral transport media (VTM) - Hanks balanced
salt solution with antibiotics
• Also known as Universal Transport Media (UTM)
• Transport of lesions, mucous membranes and throats –
specimens collected with swab
• Cell protective, protect the cell / protect the virus
 Short term transport storage 4˚C
 Long term transport(>72hours) storage-70˚C
 VTM specimens filtered (45nm filter) to eliminate
bacteria in specimen prior to being placed onto cell
monolayer
 Most likely - HSV
 Intermediate
• Adenovirus
• Influenza A and B
• Enterovirus
 Least likely
• Respiratory Syncytial Virus (RSV)
• Cytomegalovirus (CMV)
• Varicella Zoster virus (VZV)
• Amplification preferred for these viruses due to transport
issues
 Fast (@ 24-48 hours)
• HSV
 Intermediate (5 -7 days)
• Adenovirus Enterovirus
• Influenza VZV
 Slow (10 - 14 days)
• RSV
 Slowest (10 - 21 days)
• CMV
 Amplification methods desirable for most
 Double stranded DNA virus
 Eight human Herpes viruses
• Herpes simplex 1
• Herpes simplex 2
• Varicella Zoster
• Epstein Barr
• Cytomegalovirus
• Human Herpes 6, 7, and 8
 Latent infection with recurrent disease is the hallmark of
the Herpes viruses
 Latency occurs within small numbers of specific kinds of
cells, the cell type is different for each Herpes virus
 Transmission: direct contact/secretions
 Latency: dorsal root ganglia
 Diseases
• Gingivostomatitis
• Herpes labialis
• Ocular
• Encephalitis
• Neonatal
• Disseminated in immune suppressed
 Therapy – Acyclovir, Valacyclovir
 Herpes simplex 1 & 2 do well in culture
• Produce CPE within 24-48 hrs
• Human diploid fibroblast cells (MRC-5)Observe for characteristic CPE
Negative fibroblast
Cell line
HSV CPE
 Cytology/Histology – multinucleated giant cell,
intranuclear inclusions
 Cannot differentiate
from VZV
 Amplification (PCR)
 Serology – more useful for proof of past infection than
for acute diagnosis
 Transmission: close contact
 Latency: dorsal root ganglia
 Diseases:
• Chickenpox (varicella)
• Shingles (zoster – latent infection)
 Serious disease in immune suppressed or adult patients which
progress to pneumonia or encephalitis
 Histology – multi-nucleated giant cells like those of
Herpes simplex
 Serology useful for immune status check
 Amplification useful for disease diagnosis
 Effective vaccine has lowered incidence of VZV
Varicella-Zoster Diagnosis
Cell culture at 5 – 7 days
Limited # of infected foci in
monolayer
Sandpaper look to the
monolayer background with
scattered rounded cells –
Diploid fibroblast cells
Young wet vesicular lesions are best
for culture and/or molecular testing
 Transmitted by blood transfusion , vertical and
horizontal transmission to fetus, also by close contact
 Latency: Macrophages
 Disease: Infection asymptomatic in most individuals
• Congenital – most common cause of TORCH
• Perinatal
• Immunocompromised – Primary disease most serious
 Laboratory Diagnosis:
• Cell culture CPE (Human diploid fibroblast)
• PCR and quantitative PCR (best method)
• Histopathology
 Treatment: ganciclovir, foscarnet, cidofovir
Cell culture -
CMV infected fibroblast monolayer
with grape like clusters of rounded
cells
Histopathology – Intranuclear and
Intracytoplasmic inclusions – known
as OWL EYE inclusions
 Transmission - close contact, saliva
 Latency - B lymphocytes
 Diseases include:
• Infectious mononucleosis
• Lymphoreticular disease
• Oral hairy leukoplakia
• Burkitt’s lymphoma
• Nasopharyngeal Carcinoma
• 1/3 Hodgkin’s lymphoma
 Will not grow in cell culture
 Serology most used for diagnosis
EBV infection with B cell
transformation
 HA react with antigens phylogenetically
unrelated to the antigenic determinants
against which they were raised
 Human HAs secondary to EBV are detected
by the ability to react with horse or cattle
rbcs (theory of the Monospot test)
 HA rise in the first 2 - 3 weeks of EBV
infection, then rapidly fall at @ 4 weeks
VCA = viral capsid antibody
EBNA = Epstein Barr nuclear antigen
EA = early antigen
Anti-EBV antibodies Interpretation
VCA IgM VCA IgG EBNA-1 IgG
Negative Negative Negative No immunity
Positive Negative Negative Acute infection
Positive Positive Negative Acute infection
Negative Positive Positive Past infection
Negative Positive Negative Acute or past infection1
Positive Positive Positive Late primary infection
Negative Negative Positive Past infection
Serologic Diagnosis of EBV
 HH6
• Roseola [sixth disease]
• 6m-2yr high fever & rash
 HH8
• Kaposi’s sarcoma
• Castleman’s disease
• Primary effusion
lymphoma
Onion skin pattern of
Castleman disease
 DNA - non enveloped/ icosahedral virus
 Latent: lymphoid tissue
 Transmission: Respiratory and fecal-oral route
 Diseases:
• Adenovirus type 14 – virulent respiratory strain
/ pneumonia
• Pharyngitis (year round epidemics)
• Gastroenteritis in children
 Adenovirus types 40 & 41
• Kerato-conjuctivitis – red eyes @ 2 wks
• Disseminated infection in transplant patients
• Hemorrhagic cystitis in immune suppressed
 Diagnosis
• Cell culture (CPE)
 CPE in 2-5 days with round cells connected by
strands – Grows best in Heteroploid continuous
passage cell lines (HeLA, Hep-2)
• Amplification (PCR) superior for respiratory infection
• Histology - Intranuclear inclusions / smudge cells
• Stool EIA for enteric infections
• Antigen detection – staining respiratory cells by DFA
for Respiratory infections
• Supportive treatment – no specific viral therapy
Round cells with
stranding
Adenovirus Smudge cells-
and intranuclear inclusions
 DNA virus
 Parvovirus B19
• Erythema infectiosum (Fifth disease) – headache
rash and cold-like symptoms in the child
• In pregnant, infection in 1st
trimester, hydrops fetalis
leading to miscarriage
• Aplastic crisis in patients with chronic hemolytic
anemia and AIDS
• Histology - virus infects
mitotically active erythroid
precursor cells in bone marrow
• Molecular and Serology methods
to aid diagnosis
Slapped face appearance
of fifth disease
Infectious and oncogenic or
potentially oncogenic DNA
viruses
 Diseases:
 Skin and anogenital warts,
 Benign head and neck tumors,
 Cervical and anal intraepithelial neoplasia and cancer
 HPV types 16, 18, & 45 = 94% Cervical CA
 HPV types 6 and 11 = 90% Genital warts
 Pap Smear for detection of HPV
 Hybrid capture DNA probe for detection and typing
 PCR – FDA cleared platforms for detection/typing
 Three vaccines - 1°to guard against HPV 6,11,16,18
Pap smear
• JC virus [John Cunningham]
 Progressive multifocal leukoencephalopathy -
 Encephalitis of immune suppressed
 Destroys oligodendrocytes in brain
• BK virus
 Causes latent virus infection in kidney
 Progression due to immune suppression
 Hemorrhagic cystitis
• Histology/PCR to aid diagnosis
Giant Glial Cells of JCV
 Enveloped DNA – Hepadna virus
 Hepatitis B clinical disease
• 90% acute
• 1% fulminant
• 9% chronic
 Carrier state can lead to cirrhosis and
hepatic cell carcinoma
 Therapies under investigation
• Serology for diagnosis
• Vaccinate to prevent
 Surface Antigen Positive
• Active Hepatitis B or Chronic Carrier
 Do Hep B Quantitation
 Do Hep e antigen – Chronic carrier and worse prognosis
 Core Antibody Positive
• Immune due to prior infection,
acute infection or chronic carrier
Surface Antibody Positive
• Immune due to prior infection or vaccine
Hepacivirus – Hepatitis C
Flavivirus – West Nile, Dengue,
andYellow Fever
 Spread parenterally - drug abuse, blood products
or organ transplants (prior to 1992), poorly
sterilized medical equipment, sexual (low risk)
 Effects only humans and chimpanzees
 Approx 3.2 mil persons in USA have chronic
Hepatitis C
 Seven major genotypes (1-7)
• Acute self limited disease that progresses to a
disease that mainly affects the liver
• Type 1 virus most common in USA
• Infection persists in @ 75-85%/ no symptoms
• 5 - 20 % develop cirrhosis
• 1-5 % associated with hepatocellular CA
• Can require liver transplantation
 Diagnosis:
• Hepatitis C antibody test
 If Hep C antibody detected perform
 RNA quantitative assay for viral load
 Genotype of virus for proper therapy selection/duration
 Assessment of liver disease - ? cirhhosis
 No vaccine available
 Antivirals currently in clinical trials and/ or FDA
cleared that can cure >= 85% of patients infected
with Hepatitis C
•Dengue – “breakbone fever”
 Vector Aedes mosquito / Asia and the Pacific
 Fever, severe joint pain, rash
 Small % progress to hemorragic fever
 Chikungunya virus
 Vector Aedes mosquito with origin in Asia and African
continents
 Recent migration to the Caribbean and SE USA with
mosquito migration
 Travel advisory to the Caribbean
 Acute febrile illness with rash followed by extreme joint
pain, less fatalities than Dengue / no hemorrhagic phase
•Diagnosis – Serology(IgM, IgG) and PCR
 West Nile
• Vector Aedes and Culex mosquito
• Common across the US, Bird primary reservoir, horses
also at risk
• Fever, Headache, Muscle weakness, 80% asymptomatic.
Small % progress to encephalitis. Meningitis, flaccid
paralysis
 Zika virus
• Vector Aedes mosquito
• Common in South America (Brazil)
• Clinically like a mild form of Dengue
• **Microcephaly in fetuses born to infected mothers
 Diagnosis
• Immunoassays for Antibody & PCR (serum and CSF)
 >20 outbreaks since discovery in 1976
• current outbreak Dec 2013 - West Africa
• Prolonged due to area effected is high population with limited
medical reaources
 Transmission direct contact with bodily fluids – fatality rate 55%
• Animal reservoir (?) fruit bats
 Asymptomatic are not contagious
 Fever, weakness, myalgias, headache, travel history
• Consider malaria and typhoid
 Susceptible to hospital disinfectants
 Testing (EIA, PCR) at CDC – pos >= 4 days of illness
SARS - Severe Acute Respiratory Syndrome –
Outbreak in China 2003 – spread to 29 countries
Initially dry cough and/or shortness of breath development of
pneumonia by day 7-10 of illness Lymphopenia in most cases
Laboratory testing public health laboratories (CDC) -antibody
testing enzyme immunoassay (EIA) and reverse transcription
polymerase chain reaction (RT-PCR) tests for respiratory, blood, and
stool specimens.
• MERS - Middle East Respiratory Syndome
• Isolated to Arabian peninsula (2012)
• Direct contact with infected camels
• Close human to human contact can spread infection – no
outbreaks – 30% fatality rate
• Fever, rhinorrhea, cough, malaise followed by shortness of breath
 Diverse group of > 60 viruses – SS RNA
• Infections occur most often in summer and fall
• Polio virus - paralysis
 Salk vaccine Inactive Polio Vaccine (IPV)**
 Sabine vaccine Live Attenuated Vaccine (OPV)
• Coxsackie A – Herpangina
• Coxsackie B – Pericarditis/Myocarditis
• Enterovirus – Aseptic meningitis in children, hemorrhagic
conjunctivitis
• Echovirus – various infections, intestine
• Rhinoviruses – common cold
• Grow in cell culture (Diploid mixed cell – Primary Monkey
Kidney)
• PCR superior for diagnosis of meningitis (CSF) and more rapid
and sensitive for all sites
CPE of Enterovirus
Teardrop and kite like cells in
Rhesus Monkey Kidney cell culture
 Fecal – oral transmission, contaminated food or person to person
 80% develop symptoms – jaundice & elevated aminotransferases
 Usually – short incubation (15- 50 days), abrupt onset, low
mortality, no carrier state
 Diagnosis – serology, IgM positive in early infection to differ from
other Hepatitis viruses
 Antibody is protective and lasts for life
 Vaccine available
Influenza virus A
Influenza virus B
 Hemagglutinin and Neuraminidase glycoproteins spikes
on outside of viral capsid
• Gives Influenza A the H and N designations – such as
H1N1 and H3N2
• Antigenic drift - minor change in the amino acids of
either the H or N glycoprotein
 Cross antibody protection will still exist so an
epidemic will not occur
• Antigenic shift - genome re assortment with a “new”
virus created/usually from a bird or animal/ this could
create a potential pandemic
 H5N1 = Avian Influenza
 H1N1 = 2009 Influenza A
 Disease: fever, malaise …. death
 Diagnosis
• Cell culture obsolete [RMK]
• Enzyme immunoassay (EIA) on paper membrane can be used
in point of care
• Amplification (PCR) gold standard for detection
 Treatment: Amantadine and Tamiflu (Oseltamivir)
• Seasonal variation in susceptibility
 Vaccinate to prevent
 Influenza B
• Milder form of Influenza like illness
• Usually <=10% of cases /year
Measles
Parainfluenza 1,2,3,4
Mumps
Respiratory Syncytial Virus
Human Metapneumovirus
 Measles
• Fever, Rash, Dry Cough, Runny Nose,
Sore throat, inflamed eyes (photosensitive)
 Can invade lung (see HE of Lung)
• Respiratory spread - very contagious
• Koplik’s spots – bluish discoloration inner
lining of the cheek
• Subacute sclerosing panencephalitis [SSPE]
 Rare chronic degenerative neurological disease
 Persistent infection with mutated measles virus due to
lack of immune response
• Diagnosis: Clinical symptoms and Serology
• Vaccinate – MMR (Measles, Mumps, Rubella) vaccine
• Treatment: Immune globulin, vitamin A
Measlessyncytium
 Types 1,2,3, and 4
 Person to person spread
 Disease:
• Upper respiratory tract infection in adults –
more serious in immune suppressed
• Croup, bronchiolitis and pneumonia in
children
 Heteroploid cell lines (Hep-2) for culture
 PCR methods are gold standard
 Supportive therapy only available
 Person to person contact
 Classic infection is Parotitis, but can
cause infections in other sites:
T
 Respiratory disease - common cold to pneumonia, bronchiolitis to
croup, serious disease in immune suppressed
• Classic disease: Young infant with bronchiolitis
 Transmission by contact and respiratory droplet
 Specimen: Naso-phayrngeal, nasal swab, nasal lavage
 Diagnosis: EIA, cell culture (heteroploid cell lines), PCR is gold
standard, lung biopsy
 Treatment: Supportive, ribavirin Histology
Classic CPE = Syncytium formation
In heteroploid cell line
 1st
discovered in 2001 – community acquired
respiratory tract disease in the winter
 Common in young children – but can be seen in all
age groups
• @95% of cases in children <6 years of age
• Upper respiratory tract disease
• 2nd
only to RSV in the cause of bronchiolitis
 Will not grow in cell culture
 Amplification (PCR) for detection
• Specimen: Nasal swab or NP
 Treatment: Supportive
Rotavirus
 Winter - spring seasonality
• 6m-2 yrs of age most serious
• Gastroenteritis with vomiting and fluid loss –
most common cause of severe diarrhea in
children
• Fecal – oral spread
 Major cause of death in 3rd
world countries
 Diagnosis – cannot grow in cell culture
• Enzyme immunoassay, PCR
 Vaccine available
Rota = Wheel
EM Pix
Norovirus
 Spread by contaminated food and water, feces &
vomitus – takes <=20 virus particles to cause
infection – highly contagious
 Tagged the “Cruise line virus” – numerous reported
food borne epidemics on land and sea
 Leading cause of epidemic gastroenteritis – more
virulent GII.4 Sydney since spring 2012
• Fluid loss from vomiting can be debilitating
 Disease course usually limited, 24-48 hours
 PCR for diagnosis
• Cannot be grown in cell culture
Human Immunodeficiency Virus
HIV
 CD4 primary receptor site
for entry of HIV into the lymphocyte
 Reverse transcriptase enzyme
converts genomic RNA into DNA
 Transmission - sexual, blood and blood product
exposure, perinatal
 Non infectious complications:
• Lymphoma, KS, Anal cell CA, non Hodgkins
Lymphoma
Antibody EIA with Western Blot confirmation (old way)
 Positive tests must be confirmed with a Western blot test
 Western blot detects gp160/gp120 (envelope proteins), p
24 (core), and p41(reverse transcriptase)
 Must have at least 2 solid bands on Western blot to confirm
as a positive result
New test - Antigen/antibody combination (4th generation)
immunoassay* that detects IgG and IgM HIV-1 and HIV-2
antibodies and HIV-1 p24 antigen to screen for established
and acute infection
Detects infection earlier (@ 2- 4 weeks
Positive patients on either test require additional testing:
 HIV viral load quantitation >= 100 copies
 Resistance Testing – report subtype
 Most isolates in USA type B
•Monitor CD4 counts for infection severity
 Non-compliant patients or newly diagnosed
• Pneumocystis
• Cryptococcus neoformans & Histoplasma
capsulatum (disseminated)
• TB/Mycobacterium avium complex (disseminated)
• Microsporidia and Cryptosporidium (Intestinal)
• Hepatitis B
• Hepatitis C
• STD’s – Syphilis, GC, Chlamydia
 Syphilis rate high (mucosal contact)
RNA Virus
Rubella
Known as the “Three day measles” – German measles
Rash, low grade fever, cervical lymphadenopathy
Respiratory transmission
Congenital rubella –
• occurs in a developing fetus of a pregnant women
who has contracted Rubella, highest % (50%) in the
first trimester pregnancy
• Deafness, eye abnormalities, congenital heart disease
Diagnosis - Serology in combination with clinical
symptoms
Live attenuated vaccine (MMR) to prevent
Hantavirus
 USA outbreak in four corner states (NM,AZ,CO,UT)
on Indian reservation in 1993 brought attention to
this virus
 Source - Urine and secretions of wild field mice
• Deer mouse (picture) and cotton rat
 Myalgia, headache, cough and respiratory failure
 Found in states west of the Mississippi River
 Diagnosis by serology
 No therapy
Smallpox virus (Variola virus)
Vaccinia virus
 Variola virus – agent of Smallpox
 Vaccinia virus - active constituent in the Smallpox
vaccine, it is immunologically related to smallpox,
• Vaccinia can cause disease in the immune suppressed, which
prevents vaccination of this population
• Eradication of smallpox (1977)
 Disease begins as maculopapular rash and progresses to
vesicular rash -
• all lesions in same stage of development in one body area – rash
moves from central body outward
 Category A Bioterrorism agent (can maim or kill)
 Requires BSL4 laboratory (self contained lab)
 Reported to public health department for investigation
Chicken pox – Lesions in
different stage of development
Smallpox – all lesions same
stage of development
Chickenpox vs Smallpox lesions
Rabies virus
 Worldwide in animal populations
• Bat and raccoons primary reservoir in US
• Dogs in 3rd
world countries
 Post exposure shots PRIOR to the development of symptoms prevent
infection
 Rabies is a neurologic disease – classic sympton is salivation, due to
paralysis of throat muscles
 Detection of viral particles in the brain by Histologic staining known
as Negri bodies is diagnostic
 Public health department should be contacted to assist with
diagnosis
Rabies virus particles
EM showing the bullet
shaped virus
Negri bodies –
Intracytoplasmic
brain biopsy specimen
 Rare, degenerative fatal brain disorder
 Transmissable spongiform encephalopathies
(TSE) name established from the microscopic
appearance of brain with infection
 Caused by type of protein - prion
 Confirmation by brain biopsy
 Safety – prevent transmission
• Universal Precautions
• Use disposable equipment
when possible

More Related Content

What's hot

Quality Assurance in Clinical Microbiology
Quality Assurance in Clinical MicrobiologyQuality Assurance in Clinical Microbiology
Quality Assurance in Clinical Microbiology
Santosh Kumar Yadav
 
Non-Fermentative Gram negative bacilli
Non-Fermentative Gram negative bacilliNon-Fermentative Gram negative bacilli
Non-Fermentative Gram negative bacilli
Nagaraj Salapakshi
 
BLOOD CULTURING using automation
BLOOD CULTURINGusing automation BLOOD CULTURINGusing automation
BLOOD CULTURING using automation
Society for Microbiology and Infection care
 
MRSA Detection
MRSA DetectionMRSA Detection
MRSA Detection
Dr. Samira Fattah
 
Amp C (1).pptx
Amp C (1).pptxAmp C (1).pptx
Amp C (1).pptx
Rasika Deshmukh
 
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Society for Microbiology and Infection care
 
Orthomyxovirus - Morphology and laboratory diagnosis
Orthomyxovirus - Morphology and laboratory diagnosisOrthomyxovirus - Morphology and laboratory diagnosis
Orthomyxovirus - Morphology and laboratory diagnosis
Ragya Bharadwaj
 
Transfusion transmissible infections sse
Transfusion transmissible infections sseTransfusion transmissible infections sse
Transfusion transmissible infections sse
Dr Shahida Baloch
 
quality control in blood banking
quality control in blood bankingquality control in blood banking
quality control in blood banking
MLT LECTURES BY TANVEER TARA
 
Strep pneumoniae
Strep pneumoniaeStrep pneumoniae
Strep pneumoniae
Kamran Afzal, PhD.
 
56
5656
Virology 2014
Virology 2014Virology 2014
Virology 2014
Margie Morgan
 
Brucella
BrucellaBrucella
Brucella
drakmane
 
Lecture 8-streptolysin o
Lecture 8-streptolysin oLecture 8-streptolysin o
Lecture 8-streptolysin o
said warsame
 
Epidemiological marker (serotyping and bacteriocin typing)
Epidemiological marker (serotyping and bacteriocin typing)Epidemiological marker (serotyping and bacteriocin typing)
Epidemiological marker (serotyping and bacteriocin typing)
Santosh Kumar Yadav
 
Bacteriology
BacteriologyBacteriology
Bacteriology
Margie Morgan
 
ha &HIT.ppt
ha &HIT.pptha &HIT.ppt
ha &HIT.ppt
raghad ibrahim
 
Haemophilus mahadi ppt
Haemophilus mahadi pptHaemophilus mahadi ppt
Haemophilus mahadi ppt
Mahadi Mahmoud
 
laboratory diagnosis of fungal inections
laboratory diagnosis of fungal inectionslaboratory diagnosis of fungal inections
laboratory diagnosis of fungal inections
Aditi Kothari
 
15. lab diagnosis of hiv
15. lab diagnosis of hiv15. lab diagnosis of hiv
15. lab diagnosis of hiv
Dr SANTHIPRIYA GOPASANA
 

What's hot (20)

Quality Assurance in Clinical Microbiology
Quality Assurance in Clinical MicrobiologyQuality Assurance in Clinical Microbiology
Quality Assurance in Clinical Microbiology
 
Non-Fermentative Gram negative bacilli
Non-Fermentative Gram negative bacilliNon-Fermentative Gram negative bacilli
Non-Fermentative Gram negative bacilli
 
BLOOD CULTURING using automation
BLOOD CULTURINGusing automation BLOOD CULTURINGusing automation
BLOOD CULTURING using automation
 
MRSA Detection
MRSA DetectionMRSA Detection
MRSA Detection
 
Amp C (1).pptx
Amp C (1).pptxAmp C (1).pptx
Amp C (1).pptx
 
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
 
Orthomyxovirus - Morphology and laboratory diagnosis
Orthomyxovirus - Morphology and laboratory diagnosisOrthomyxovirus - Morphology and laboratory diagnosis
Orthomyxovirus - Morphology and laboratory diagnosis
 
Transfusion transmissible infections sse
Transfusion transmissible infections sseTransfusion transmissible infections sse
Transfusion transmissible infections sse
 
quality control in blood banking
quality control in blood bankingquality control in blood banking
quality control in blood banking
 
Strep pneumoniae
Strep pneumoniaeStrep pneumoniae
Strep pneumoniae
 
56
5656
56
 
Virology 2014
Virology 2014Virology 2014
Virology 2014
 
Brucella
BrucellaBrucella
Brucella
 
Lecture 8-streptolysin o
Lecture 8-streptolysin oLecture 8-streptolysin o
Lecture 8-streptolysin o
 
Epidemiological marker (serotyping and bacteriocin typing)
Epidemiological marker (serotyping and bacteriocin typing)Epidemiological marker (serotyping and bacteriocin typing)
Epidemiological marker (serotyping and bacteriocin typing)
 
Bacteriology
BacteriologyBacteriology
Bacteriology
 
ha &HIT.ppt
ha &HIT.pptha &HIT.ppt
ha &HIT.ppt
 
Haemophilus mahadi ppt
Haemophilus mahadi pptHaemophilus mahadi ppt
Haemophilus mahadi ppt
 
laboratory diagnosis of fungal inections
laboratory diagnosis of fungal inectionslaboratory diagnosis of fungal inections
laboratory diagnosis of fungal inections
 
15. lab diagnosis of hiv
15. lab diagnosis of hiv15. lab diagnosis of hiv
15. lab diagnosis of hiv
 

Viewers also liked

Virology Update 2017
Virology Update 2017Virology Update 2017
Virology Update 2017
Margie Morgan
 
Mycobacteriology 2016
Mycobacteriology 2016Mycobacteriology 2016
Mycobacteriology 2016
Margie Morgan
 
Website mycobacteriology 2017 update
Website  mycobacteriology 2017 updateWebsite  mycobacteriology 2017 update
Website mycobacteriology 2017 update
Margie Morgan
 
Parasitology Review 2017
Parasitology Review 2017Parasitology Review 2017
Parasitology Review 2017
Margie Morgan
 
Bacteriology 2017 Update
Bacteriology 2017 UpdateBacteriology 2017 Update
Bacteriology 2017 Update
Margie Morgan
 
Mycology 2016
Mycology 2016Mycology 2016
Mycology 2016
Margie Morgan
 
Mycology Update 2017
Mycology Update 2017Mycology Update 2017
Mycology Update 2017
Margie Morgan
 
Gram Stains Update 2017
Gram Stains Update 2017Gram Stains Update 2017
Gram Stains Update 2017
Margie Morgan
 
Antibiotic Senstivity Testing 2017 Update
Antibiotic Senstivity Testing 2017 UpdateAntibiotic Senstivity Testing 2017 Update
Antibiotic Senstivity Testing 2017 Update
Margie Morgan
 

Viewers also liked (9)

Virology Update 2017
Virology Update 2017Virology Update 2017
Virology Update 2017
 
Mycobacteriology 2016
Mycobacteriology 2016Mycobacteriology 2016
Mycobacteriology 2016
 
Website mycobacteriology 2017 update
Website  mycobacteriology 2017 updateWebsite  mycobacteriology 2017 update
Website mycobacteriology 2017 update
 
Parasitology Review 2017
Parasitology Review 2017Parasitology Review 2017
Parasitology Review 2017
 
Bacteriology 2017 Update
Bacteriology 2017 UpdateBacteriology 2017 Update
Bacteriology 2017 Update
 
Mycology 2016
Mycology 2016Mycology 2016
Mycology 2016
 
Mycology Update 2017
Mycology Update 2017Mycology Update 2017
Mycology Update 2017
 
Gram Stains Update 2017
Gram Stains Update 2017Gram Stains Update 2017
Gram Stains Update 2017
 
Antibiotic Senstivity Testing 2017 Update
Antibiotic Senstivity Testing 2017 UpdateAntibiotic Senstivity Testing 2017 Update
Antibiotic Senstivity Testing 2017 Update
 

Similar to Virology 2016

Virology 2018
Virology 2018Virology 2018
Virology 2018
Margie Morgan
 
Virology Review 2019
Virology Review 2019Virology Review 2019
Virology Review 2019
Margie Morgan
 
Virology Review 2020
Virology Review 2020Virology Review 2020
Virology Review 2020
Margie Morgan
 
Virology 2021
Virology 2021Virology 2021
Virology 2021
Margie Morgan
 
Virology 2022
Virology 2022Virology 2022
Virology 2022
Margie Morgan
 
Virology 2024 | Microbes with Morgan 2024
Virology 2024 | Microbes with Morgan 2024Virology 2024 | Microbes with Morgan 2024
Virology 2024 | Microbes with Morgan 2024
Margie Morgan
 
VIROLOGY REVIEW 2023
VIROLOGY REVIEW 2023VIROLOGY REVIEW 2023
VIROLOGY REVIEW 2023
Margie Morgan
 
Virology Review
Virology ReviewVirology Review
Virology Review
Margie Morgan
 
Human cmv in immuncompromised and congential patients 2019
Human cmv in immuncompromised and congential patients  2019Human cmv in immuncompromised and congential patients  2019
Human cmv in immuncompromised and congential patients 2019
Mohammed AL toubi
 
Viral Haemorrhagic Fevers
Viral Haemorrhagic FeversViral Haemorrhagic Fevers
Viral Haemorrhagic Fevers
autumnpianist
 
Lab dig virus
Lab dig virusLab dig virus
Lab dig virus
Prbn Shah
 
Viral tests
Viral testsViral tests
Viral tests
Sayantan Banerjee
 
Dna viruses
Dna virusesDna viruses
Dna viruses
TONY SCARIA
 
adenovirus powerpoint.ppt
adenovirus powerpoint.pptadenovirus powerpoint.ppt
adenovirus powerpoint.ppt
Neelam Joshi
 
Herpesviruses
HerpesvirusesHerpesviruses
Chicken pox(varicella).pptx
Chicken pox(varicella).pptxChicken pox(varicella).pptx
Chicken pox(varicella).pptx
samaritabanik
 
Viro
ViroViro
Viro
ViroViro
PICORNA VIRUS POLIO dr. someshwaran may 2015
PICORNA VIRUS POLIO dr. someshwaran may 2015 PICORNA VIRUS POLIO dr. someshwaran may 2015
PICORNA VIRUS POLIO dr. someshwaran may 2015
SOMESHWARAN R
 
PrecriptionPiont - 2.ppt
PrecriptionPiont - 2.pptPrecriptionPiont - 2.ppt
PrecriptionPiont - 2.ppt
RajKumarSingha5
 

Similar to Virology 2016 (20)

Virology 2018
Virology 2018Virology 2018
Virology 2018
 
Virology Review 2019
Virology Review 2019Virology Review 2019
Virology Review 2019
 
Virology Review 2020
Virology Review 2020Virology Review 2020
Virology Review 2020
 
Virology 2021
Virology 2021Virology 2021
Virology 2021
 
Virology 2022
Virology 2022Virology 2022
Virology 2022
 
Virology 2024 | Microbes with Morgan 2024
Virology 2024 | Microbes with Morgan 2024Virology 2024 | Microbes with Morgan 2024
Virology 2024 | Microbes with Morgan 2024
 
VIROLOGY REVIEW 2023
VIROLOGY REVIEW 2023VIROLOGY REVIEW 2023
VIROLOGY REVIEW 2023
 
Virology Review
Virology ReviewVirology Review
Virology Review
 
Human cmv in immuncompromised and congential patients 2019
Human cmv in immuncompromised and congential patients  2019Human cmv in immuncompromised and congential patients  2019
Human cmv in immuncompromised and congential patients 2019
 
Viral Haemorrhagic Fevers
Viral Haemorrhagic FeversViral Haemorrhagic Fevers
Viral Haemorrhagic Fevers
 
Lab dig virus
Lab dig virusLab dig virus
Lab dig virus
 
Viral tests
Viral testsViral tests
Viral tests
 
Dna viruses
Dna virusesDna viruses
Dna viruses
 
adenovirus powerpoint.ppt
adenovirus powerpoint.pptadenovirus powerpoint.ppt
adenovirus powerpoint.ppt
 
Herpesviruses
HerpesvirusesHerpesviruses
Herpesviruses
 
Chicken pox(varicella).pptx
Chicken pox(varicella).pptxChicken pox(varicella).pptx
Chicken pox(varicella).pptx
 
Viro
ViroViro
Viro
 
Viro
ViroViro
Viro
 
PICORNA VIRUS POLIO dr. someshwaran may 2015
PICORNA VIRUS POLIO dr. someshwaran may 2015 PICORNA VIRUS POLIO dr. someshwaran may 2015
PICORNA VIRUS POLIO dr. someshwaran may 2015
 
PrecriptionPiont - 2.ppt
PrecriptionPiont - 2.pptPrecriptionPiont - 2.ppt
PrecriptionPiont - 2.ppt
 

More from Margie Morgan

Susceptibility Update 2024 | Microbes with Morgan
Susceptibility Update 2024 | Microbes with MorganSusceptibility Update 2024 | Microbes with Morgan
Susceptibility Update 2024 | Microbes with Morgan
Margie Morgan
 
WEB BACTERIOLOGY 2024 | Microbes With Morgan
WEB BACTERIOLOGY 2024 | Microbes With MorganWEB BACTERIOLOGY 2024 | Microbes With Morgan
WEB BACTERIOLOGY 2024 | Microbes With Morgan
Margie Morgan
 
Parasitology 2024 | Microbes with Morgan
Parasitology 2024 | Microbes with MorganParasitology 2024 | Microbes with Morgan
Parasitology 2024 | Microbes with Morgan
Margie Morgan
 
Mycobacteriology update 2024 Margie Morgan.ppt
Mycobacteriology update 2024 Margie Morgan.pptMycobacteriology update 2024 Margie Morgan.ppt
Mycobacteriology update 2024 Margie Morgan.ppt
Margie Morgan
 
Mycology Update February 2024 Microbes with Morgan
Mycology Update February 2024 Microbes with MorganMycology Update February 2024 Microbes with Morgan
Mycology Update February 2024 Microbes with Morgan
Margie Morgan
 
Web Bacteriology 2023
Web Bacteriology 2023Web Bacteriology 2023
Web Bacteriology 2023
Margie Morgan
 
Gram Stain 2023
Gram Stain 2023Gram Stain 2023
Gram Stain 2023
Margie Morgan
 
Mycology Update 2023
Mycology Update 2023Mycology Update 2023
Mycology Update 2023
Margie Morgan
 
Mycobacteriology Update 2023
Mycobacteriology Update 2023Mycobacteriology Update 2023
Mycobacteriology Update 2023
Margie Morgan
 
Mycology 2022
Mycology 2022Mycology 2022
Mycology 2022
Margie Morgan
 
Mycobacteriology 2022
Mycobacteriology 2022Mycobacteriology 2022
Mycobacteriology 2022
Margie Morgan
 
Bacteriology Update 2021 (Part 2.)
Bacteriology Update 2021 (Part 2.)Bacteriology Update 2021 (Part 2.)
Bacteriology Update 2021 (Part 2.)
Margie Morgan
 
Bacteriology Update 2021 (Part 1.)
Bacteriology Update 2021 (Part 1.)Bacteriology Update 2021 (Part 1.)
Bacteriology Update 2021 (Part 1.)
Margie Morgan
 
Gram Stains 2021
Gram Stains 2021Gram Stains 2021
Gram Stains 2021
Margie Morgan
 
Mycobacteriology 2021
Mycobacteriology 2021Mycobacteriology 2021
Mycobacteriology 2021
Margie Morgan
 
Mycology Update 2021
Mycology Update 2021Mycology Update 2021
Mycology Update 2021
Margie Morgan
 
Parasitology 2020
Parasitology 2020Parasitology 2020
Parasitology 2020
Margie Morgan
 
Bacteriology Update 2020
Bacteriology Update 2020Bacteriology Update 2020
Bacteriology Update 2020
Margie Morgan
 
Antibiotic Sensitivity Testing 2020 Update
Antibiotic Sensitivity Testing 2020 Update Antibiotic Sensitivity Testing 2020 Update
Antibiotic Sensitivity Testing 2020 Update
Margie Morgan
 
Mycobacteriology 2020
Mycobacteriology 2020Mycobacteriology 2020
Mycobacteriology 2020
Margie Morgan
 

More from Margie Morgan (20)

Susceptibility Update 2024 | Microbes with Morgan
Susceptibility Update 2024 | Microbes with MorganSusceptibility Update 2024 | Microbes with Morgan
Susceptibility Update 2024 | Microbes with Morgan
 
WEB BACTERIOLOGY 2024 | Microbes With Morgan
WEB BACTERIOLOGY 2024 | Microbes With MorganWEB BACTERIOLOGY 2024 | Microbes With Morgan
WEB BACTERIOLOGY 2024 | Microbes With Morgan
 
Parasitology 2024 | Microbes with Morgan
Parasitology 2024 | Microbes with MorganParasitology 2024 | Microbes with Morgan
Parasitology 2024 | Microbes with Morgan
 
Mycobacteriology update 2024 Margie Morgan.ppt
Mycobacteriology update 2024 Margie Morgan.pptMycobacteriology update 2024 Margie Morgan.ppt
Mycobacteriology update 2024 Margie Morgan.ppt
 
Mycology Update February 2024 Microbes with Morgan
Mycology Update February 2024 Microbes with MorganMycology Update February 2024 Microbes with Morgan
Mycology Update February 2024 Microbes with Morgan
 
Web Bacteriology 2023
Web Bacteriology 2023Web Bacteriology 2023
Web Bacteriology 2023
 
Gram Stain 2023
Gram Stain 2023Gram Stain 2023
Gram Stain 2023
 
Mycology Update 2023
Mycology Update 2023Mycology Update 2023
Mycology Update 2023
 
Mycobacteriology Update 2023
Mycobacteriology Update 2023Mycobacteriology Update 2023
Mycobacteriology Update 2023
 
Mycology 2022
Mycology 2022Mycology 2022
Mycology 2022
 
Mycobacteriology 2022
Mycobacteriology 2022Mycobacteriology 2022
Mycobacteriology 2022
 
Bacteriology Update 2021 (Part 2.)
Bacteriology Update 2021 (Part 2.)Bacteriology Update 2021 (Part 2.)
Bacteriology Update 2021 (Part 2.)
 
Bacteriology Update 2021 (Part 1.)
Bacteriology Update 2021 (Part 1.)Bacteriology Update 2021 (Part 1.)
Bacteriology Update 2021 (Part 1.)
 
Gram Stains 2021
Gram Stains 2021Gram Stains 2021
Gram Stains 2021
 
Mycobacteriology 2021
Mycobacteriology 2021Mycobacteriology 2021
Mycobacteriology 2021
 
Mycology Update 2021
Mycology Update 2021Mycology Update 2021
Mycology Update 2021
 
Parasitology 2020
Parasitology 2020Parasitology 2020
Parasitology 2020
 
Bacteriology Update 2020
Bacteriology Update 2020Bacteriology Update 2020
Bacteriology Update 2020
 
Antibiotic Sensitivity Testing 2020 Update
Antibiotic Sensitivity Testing 2020 Update Antibiotic Sensitivity Testing 2020 Update
Antibiotic Sensitivity Testing 2020 Update
 
Mycobacteriology 2020
Mycobacteriology 2020Mycobacteriology 2020
Mycobacteriology 2020
 

Recently uploaded

Management of Post Operative Pain: to make doctors conscious about the benefi...
Management of Post Operative Pain: to make doctors conscious about the benefi...Management of Post Operative Pain: to make doctors conscious about the benefi...
Management of Post Operative Pain: to make doctors conscious about the benefi...
Nilima65
 
Columbia毕业证书退学办理
Columbia毕业证书退学办理Columbia毕业证书退学办理
Columbia毕业证书退学办理
ozcot
 
Monopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in TripuraMonopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in Tripura
SKG Internationals
 
National Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptxNational Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptx
Jyoti Chand
 
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdfCHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
Sachin Sharma
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
rightmanforbloodline
 
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
Santhosh Raj
 
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdfnhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
Carolyn Harker
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
gjsma0ep
 
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 FaridkotFaridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
varun0kumar00
 
Mohali Call Girls 7742996321 Call Girls Mohali
Mohali Call Girls  7742996321 Call Girls  MohaliMohali Call Girls  7742996321 Call Girls  Mohali
Mohali Call Girls 7742996321 Call Girls Mohali
Digital Marketing
 
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
DrDevTaneja1
 
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 BathindaBathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
varun0kumar00
 
Know Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdfKnow Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdf
Dr. Sujit Chatterjee CEO Hiranandani Hospital
 
nurs fpx 4050 assessment 4 final care coordination plan.pdf
nurs fpx 4050 assessment 4 final care coordination plan.pdfnurs fpx 4050 assessment 4 final care coordination plan.pdf
nurs fpx 4050 assessment 4 final care coordination plan.pdf
Carolyn Harker
 
3. User Guide Activity Budget Tracking App Steps to apply.pptx
3. User Guide Activity Budget Tracking App Steps to apply.pptx3. User Guide Activity Budget Tracking App Steps to apply.pptx
3. User Guide Activity Budget Tracking App Steps to apply.pptx
habtegirma
 
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPTNURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
blessyjannu21
 
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
rightmanforbloodline
 
Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -
Gokul Rangarajan
 
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell
 

Recently uploaded (20)

Management of Post Operative Pain: to make doctors conscious about the benefi...
Management of Post Operative Pain: to make doctors conscious about the benefi...Management of Post Operative Pain: to make doctors conscious about the benefi...
Management of Post Operative Pain: to make doctors conscious about the benefi...
 
Columbia毕业证书退学办理
Columbia毕业证书退学办理Columbia毕业证书退学办理
Columbia毕业证书退学办理
 
Monopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in TripuraMonopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in Tripura
 
National Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptxNational Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptx
 
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdfCHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
 
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
 
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdfnhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
nhs fpx 4000 assessment 4 analyzing a current health care problem or issue.pdf
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
 
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 FaridkotFaridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
 
Mohali Call Girls 7742996321 Call Girls Mohali
Mohali Call Girls  7742996321 Call Girls  MohaliMohali Call Girls  7742996321 Call Girls  Mohali
Mohali Call Girls 7742996321 Call Girls Mohali
 
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
 
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 BathindaBathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
 
Know Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdfKnow Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdf
 
nurs fpx 4050 assessment 4 final care coordination plan.pdf
nurs fpx 4050 assessment 4 final care coordination plan.pdfnurs fpx 4050 assessment 4 final care coordination plan.pdf
nurs fpx 4050 assessment 4 final care coordination plan.pdf
 
3. User Guide Activity Budget Tracking App Steps to apply.pptx
3. User Guide Activity Budget Tracking App Steps to apply.pptx3. User Guide Activity Budget Tracking App Steps to apply.pptx
3. User Guide Activity Budget Tracking App Steps to apply.pptx
 
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPTNURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
 
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
 
Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -
 
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
 

Virology 2016

  • 1. Margie Morgan, PhD, MT(ASCP), D(ABMM) microbeswithmorgan.com
  • 2. 1.Direct Staining for Antigen 2. Enzyme Immunoassay 3. Molecular Amplification 4.Viral Cell Culture
  • 3.  Direct Fluorescent antibody (DFA) stain  Collect cells from base of fresh vesicular lesion  Stain with Fl antibody specific for HSV and/or VZV  Look for fluorescent cells (virus infected) using fluorescence microscope  More sensitive & specific method than Tzanck prep for virus detection (DFA 80% vs. Tzanck 50%)  Tzanck prep= Giemsa staining cells from lesion -/examine for multinucleated giant cells of Herpes virus Tzanck Tzanck DFA
  • 4. • Enzyme immunoassay (EIA) –  Antigen/antibody complex formed – then bound to a color producing substrate  Used most often  Detection of non-culturable viruses – Rotavirus  Influenza A and B , & Respiratory syncytial virus (RSV) from nasal/NP swab – point of care • Membrane EIA Liquid/well EIA
  • 5.  Molecular Amplification (DNA or RNA) • Rapid/Sensitive/Specific for numerous viruses • Exceeds sensitivity of culture/ new Gold standard  Respiratory viruses  HSV and Enterovirus detection from CSF  Culture <=20% PCR >=90%  Tests of diagnosis not cure – can shed residual virus for 7 – 30 days after initial positive test • CMV - Quantitative assays in transplantation • Hepatitis B and C detection and viral load • HIV viral load
  • 6. • Inner tube wall coated with monolayer of cells plus liquid growth media • Three types of cell lines:  Primary cell lines – direct from animal or human organ into culture tube subculture once  Rhesus monkey kidney-RMK  Diploid – semi continuous cell lines– Can survive 20 – 50 subcultures into new vials –  Human diploid fibroblast cells, example: MRC-5-Microbiology Research Council 5  Continuous cell lines – can survive continuous passage into new vials,  Tumor lineage, HEp-2 and HeLa
  • 7.  Patient specimens inoculated into cell culture tubes, incubated, then read under light microscopy for “Cytopathic effect” – the effect the virus has on the cell monolayer • The pattern of destruction is specific for each virus type
  • 8. Spin Down Shell Vial Culture – •Speed up virus detection •Cell monolayer on coverslip/vial •Specimen inoculated into vial •Centrifuge vial to induce virus invasion into cells •Incubate @ 35C, 24-72 hours •Direct fluorescent antibody stain of coverslip – target early virus antigens (those first formed ) Cover slip
  • 9.  Viral transport media (VTM) - Hanks balanced salt solution with antibiotics • Also known as Universal Transport Media (UTM) • Transport of lesions, mucous membranes and throats – specimens collected with swab • Cell protective, protect the cell / protect the virus  Short term transport storage 4˚C  Long term transport(>72hours) storage-70˚C  VTM specimens filtered (45nm filter) to eliminate bacteria in specimen prior to being placed onto cell monolayer
  • 10.  Most likely - HSV  Intermediate • Adenovirus • Influenza A and B • Enterovirus  Least likely • Respiratory Syncytial Virus (RSV) • Cytomegalovirus (CMV) • Varicella Zoster virus (VZV) • Amplification preferred for these viruses due to transport issues
  • 11.  Fast (@ 24-48 hours) • HSV  Intermediate (5 -7 days) • Adenovirus Enterovirus • Influenza VZV  Slow (10 - 14 days) • RSV  Slowest (10 - 21 days) • CMV  Amplification methods desirable for most
  • 12.
  • 13.  Double stranded DNA virus  Eight human Herpes viruses • Herpes simplex 1 • Herpes simplex 2 • Varicella Zoster • Epstein Barr • Cytomegalovirus • Human Herpes 6, 7, and 8  Latent infection with recurrent disease is the hallmark of the Herpes viruses  Latency occurs within small numbers of specific kinds of cells, the cell type is different for each Herpes virus
  • 14.  Transmission: direct contact/secretions  Latency: dorsal root ganglia  Diseases • Gingivostomatitis • Herpes labialis • Ocular • Encephalitis • Neonatal • Disseminated in immune suppressed  Therapy – Acyclovir, Valacyclovir
  • 15.  Herpes simplex 1 & 2 do well in culture • Produce CPE within 24-48 hrs • Human diploid fibroblast cells (MRC-5)Observe for characteristic CPE Negative fibroblast Cell line HSV CPE
  • 16.  Cytology/Histology – multinucleated giant cell, intranuclear inclusions  Cannot differentiate from VZV  Amplification (PCR)  Serology – more useful for proof of past infection than for acute diagnosis
  • 17.  Transmission: close contact  Latency: dorsal root ganglia  Diseases: • Chickenpox (varicella) • Shingles (zoster – latent infection)  Serious disease in immune suppressed or adult patients which progress to pneumonia or encephalitis  Histology – multi-nucleated giant cells like those of Herpes simplex  Serology useful for immune status check  Amplification useful for disease diagnosis  Effective vaccine has lowered incidence of VZV
  • 18. Varicella-Zoster Diagnosis Cell culture at 5 – 7 days Limited # of infected foci in monolayer Sandpaper look to the monolayer background with scattered rounded cells – Diploid fibroblast cells Young wet vesicular lesions are best for culture and/or molecular testing
  • 19.  Transmitted by blood transfusion , vertical and horizontal transmission to fetus, also by close contact  Latency: Macrophages  Disease: Infection asymptomatic in most individuals • Congenital – most common cause of TORCH • Perinatal • Immunocompromised – Primary disease most serious  Laboratory Diagnosis: • Cell culture CPE (Human diploid fibroblast) • PCR and quantitative PCR (best method) • Histopathology  Treatment: ganciclovir, foscarnet, cidofovir
  • 20. Cell culture - CMV infected fibroblast monolayer with grape like clusters of rounded cells Histopathology – Intranuclear and Intracytoplasmic inclusions – known as OWL EYE inclusions
  • 21.  Transmission - close contact, saliva  Latency - B lymphocytes  Diseases include: • Infectious mononucleosis • Lymphoreticular disease • Oral hairy leukoplakia • Burkitt’s lymphoma • Nasopharyngeal Carcinoma • 1/3 Hodgkin’s lymphoma  Will not grow in cell culture  Serology most used for diagnosis EBV infection with B cell transformation
  • 22.  HA react with antigens phylogenetically unrelated to the antigenic determinants against which they were raised  Human HAs secondary to EBV are detected by the ability to react with horse or cattle rbcs (theory of the Monospot test)  HA rise in the first 2 - 3 weeks of EBV infection, then rapidly fall at @ 4 weeks
  • 23. VCA = viral capsid antibody EBNA = Epstein Barr nuclear antigen EA = early antigen
  • 24. Anti-EBV antibodies Interpretation VCA IgM VCA IgG EBNA-1 IgG Negative Negative Negative No immunity Positive Negative Negative Acute infection Positive Positive Negative Acute infection Negative Positive Positive Past infection Negative Positive Negative Acute or past infection1 Positive Positive Positive Late primary infection Negative Negative Positive Past infection Serologic Diagnosis of EBV
  • 25.  HH6 • Roseola [sixth disease] • 6m-2yr high fever & rash  HH8 • Kaposi’s sarcoma • Castleman’s disease • Primary effusion lymphoma Onion skin pattern of Castleman disease
  • 26.
  • 27.  DNA - non enveloped/ icosahedral virus  Latent: lymphoid tissue  Transmission: Respiratory and fecal-oral route  Diseases: • Adenovirus type 14 – virulent respiratory strain / pneumonia • Pharyngitis (year round epidemics) • Gastroenteritis in children  Adenovirus types 40 & 41 • Kerato-conjuctivitis – red eyes @ 2 wks • Disseminated infection in transplant patients • Hemorrhagic cystitis in immune suppressed
  • 28.  Diagnosis • Cell culture (CPE)  CPE in 2-5 days with round cells connected by strands – Grows best in Heteroploid continuous passage cell lines (HeLA, Hep-2) • Amplification (PCR) superior for respiratory infection • Histology - Intranuclear inclusions / smudge cells • Stool EIA for enteric infections • Antigen detection – staining respiratory cells by DFA for Respiratory infections • Supportive treatment – no specific viral therapy Round cells with stranding
  • 29. Adenovirus Smudge cells- and intranuclear inclusions
  • 30.
  • 31.  DNA virus  Parvovirus B19 • Erythema infectiosum (Fifth disease) – headache rash and cold-like symptoms in the child • In pregnant, infection in 1st trimester, hydrops fetalis leading to miscarriage • Aplastic crisis in patients with chronic hemolytic anemia and AIDS • Histology - virus infects mitotically active erythroid precursor cells in bone marrow • Molecular and Serology methods to aid diagnosis Slapped face appearance of fifth disease
  • 32. Infectious and oncogenic or potentially oncogenic DNA viruses
  • 33.  Diseases:  Skin and anogenital warts,  Benign head and neck tumors,  Cervical and anal intraepithelial neoplasia and cancer  HPV types 16, 18, & 45 = 94% Cervical CA  HPV types 6 and 11 = 90% Genital warts  Pap Smear for detection of HPV  Hybrid capture DNA probe for detection and typing  PCR – FDA cleared platforms for detection/typing  Three vaccines - 1°to guard against HPV 6,11,16,18 Pap smear
  • 34. • JC virus [John Cunningham]  Progressive multifocal leukoencephalopathy -  Encephalitis of immune suppressed  Destroys oligodendrocytes in brain • BK virus  Causes latent virus infection in kidney  Progression due to immune suppression  Hemorrhagic cystitis • Histology/PCR to aid diagnosis Giant Glial Cells of JCV
  • 35.
  • 36.  Enveloped DNA – Hepadna virus  Hepatitis B clinical disease • 90% acute • 1% fulminant • 9% chronic  Carrier state can lead to cirrhosis and hepatic cell carcinoma  Therapies under investigation • Serology for diagnosis • Vaccinate to prevent
  • 37.  Surface Antigen Positive • Active Hepatitis B or Chronic Carrier  Do Hep B Quantitation  Do Hep e antigen – Chronic carrier and worse prognosis  Core Antibody Positive • Immune due to prior infection, acute infection or chronic carrier Surface Antibody Positive • Immune due to prior infection or vaccine
  • 38. Hepacivirus – Hepatitis C Flavivirus – West Nile, Dengue, andYellow Fever
  • 39.  Spread parenterally - drug abuse, blood products or organ transplants (prior to 1992), poorly sterilized medical equipment, sexual (low risk)  Effects only humans and chimpanzees  Approx 3.2 mil persons in USA have chronic Hepatitis C  Seven major genotypes (1-7) • Acute self limited disease that progresses to a disease that mainly affects the liver • Type 1 virus most common in USA • Infection persists in @ 75-85%/ no symptoms • 5 - 20 % develop cirrhosis • 1-5 % associated with hepatocellular CA • Can require liver transplantation
  • 40.  Diagnosis: • Hepatitis C antibody test  If Hep C antibody detected perform  RNA quantitative assay for viral load  Genotype of virus for proper therapy selection/duration  Assessment of liver disease - ? cirhhosis  No vaccine available  Antivirals currently in clinical trials and/ or FDA cleared that can cure >= 85% of patients infected with Hepatitis C
  • 41. •Dengue – “breakbone fever”  Vector Aedes mosquito / Asia and the Pacific  Fever, severe joint pain, rash  Small % progress to hemorragic fever  Chikungunya virus  Vector Aedes mosquito with origin in Asia and African continents  Recent migration to the Caribbean and SE USA with mosquito migration  Travel advisory to the Caribbean  Acute febrile illness with rash followed by extreme joint pain, less fatalities than Dengue / no hemorrhagic phase •Diagnosis – Serology(IgM, IgG) and PCR
  • 42.  West Nile • Vector Aedes and Culex mosquito • Common across the US, Bird primary reservoir, horses also at risk • Fever, Headache, Muscle weakness, 80% asymptomatic. Small % progress to encephalitis. Meningitis, flaccid paralysis  Zika virus • Vector Aedes mosquito • Common in South America (Brazil) • Clinically like a mild form of Dengue • **Microcephaly in fetuses born to infected mothers  Diagnosis • Immunoassays for Antibody & PCR (serum and CSF)
  • 43.  >20 outbreaks since discovery in 1976 • current outbreak Dec 2013 - West Africa • Prolonged due to area effected is high population with limited medical reaources  Transmission direct contact with bodily fluids – fatality rate 55% • Animal reservoir (?) fruit bats  Asymptomatic are not contagious  Fever, weakness, myalgias, headache, travel history • Consider malaria and typhoid  Susceptible to hospital disinfectants  Testing (EIA, PCR) at CDC – pos >= 4 days of illness
  • 44. SARS - Severe Acute Respiratory Syndrome – Outbreak in China 2003 – spread to 29 countries Initially dry cough and/or shortness of breath development of pneumonia by day 7-10 of illness Lymphopenia in most cases Laboratory testing public health laboratories (CDC) -antibody testing enzyme immunoassay (EIA) and reverse transcription polymerase chain reaction (RT-PCR) tests for respiratory, blood, and stool specimens. • MERS - Middle East Respiratory Syndome • Isolated to Arabian peninsula (2012) • Direct contact with infected camels • Close human to human contact can spread infection – no outbreaks – 30% fatality rate • Fever, rhinorrhea, cough, malaise followed by shortness of breath
  • 45.
  • 46.  Diverse group of > 60 viruses – SS RNA • Infections occur most often in summer and fall • Polio virus - paralysis  Salk vaccine Inactive Polio Vaccine (IPV)**  Sabine vaccine Live Attenuated Vaccine (OPV) • Coxsackie A – Herpangina • Coxsackie B – Pericarditis/Myocarditis • Enterovirus – Aseptic meningitis in children, hemorrhagic conjunctivitis • Echovirus – various infections, intestine • Rhinoviruses – common cold • Grow in cell culture (Diploid mixed cell – Primary Monkey Kidney) • PCR superior for diagnosis of meningitis (CSF) and more rapid and sensitive for all sites
  • 47. CPE of Enterovirus Teardrop and kite like cells in Rhesus Monkey Kidney cell culture
  • 48.  Fecal – oral transmission, contaminated food or person to person  80% develop symptoms – jaundice & elevated aminotransferases  Usually – short incubation (15- 50 days), abrupt onset, low mortality, no carrier state  Diagnosis – serology, IgM positive in early infection to differ from other Hepatitis viruses  Antibody is protective and lasts for life  Vaccine available
  • 50.  Hemagglutinin and Neuraminidase glycoproteins spikes on outside of viral capsid • Gives Influenza A the H and N designations – such as H1N1 and H3N2 • Antigenic drift - minor change in the amino acids of either the H or N glycoprotein  Cross antibody protection will still exist so an epidemic will not occur • Antigenic shift - genome re assortment with a “new” virus created/usually from a bird or animal/ this could create a potential pandemic  H5N1 = Avian Influenza  H1N1 = 2009 Influenza A
  • 51.  Disease: fever, malaise …. death  Diagnosis • Cell culture obsolete [RMK] • Enzyme immunoassay (EIA) on paper membrane can be used in point of care • Amplification (PCR) gold standard for detection  Treatment: Amantadine and Tamiflu (Oseltamivir) • Seasonal variation in susceptibility  Vaccinate to prevent  Influenza B • Milder form of Influenza like illness • Usually <=10% of cases /year
  • 53.  Measles • Fever, Rash, Dry Cough, Runny Nose, Sore throat, inflamed eyes (photosensitive)  Can invade lung (see HE of Lung) • Respiratory spread - very contagious • Koplik’s spots – bluish discoloration inner lining of the cheek • Subacute sclerosing panencephalitis [SSPE]  Rare chronic degenerative neurological disease  Persistent infection with mutated measles virus due to lack of immune response • Diagnosis: Clinical symptoms and Serology • Vaccinate – MMR (Measles, Mumps, Rubella) vaccine • Treatment: Immune globulin, vitamin A Measlessyncytium
  • 54.  Types 1,2,3, and 4  Person to person spread  Disease: • Upper respiratory tract infection in adults – more serious in immune suppressed • Croup, bronchiolitis and pneumonia in children  Heteroploid cell lines (Hep-2) for culture  PCR methods are gold standard  Supportive therapy only available
  • 55.  Person to person contact  Classic infection is Parotitis, but can cause infections in other sites: T
  • 56.  Respiratory disease - common cold to pneumonia, bronchiolitis to croup, serious disease in immune suppressed • Classic disease: Young infant with bronchiolitis  Transmission by contact and respiratory droplet  Specimen: Naso-phayrngeal, nasal swab, nasal lavage  Diagnosis: EIA, cell culture (heteroploid cell lines), PCR is gold standard, lung biopsy  Treatment: Supportive, ribavirin Histology Classic CPE = Syncytium formation In heteroploid cell line
  • 57.  1st discovered in 2001 – community acquired respiratory tract disease in the winter  Common in young children – but can be seen in all age groups • @95% of cases in children <6 years of age • Upper respiratory tract disease • 2nd only to RSV in the cause of bronchiolitis  Will not grow in cell culture  Amplification (PCR) for detection • Specimen: Nasal swab or NP  Treatment: Supportive
  • 59.  Winter - spring seasonality • 6m-2 yrs of age most serious • Gastroenteritis with vomiting and fluid loss – most common cause of severe diarrhea in children • Fecal – oral spread  Major cause of death in 3rd world countries  Diagnosis – cannot grow in cell culture • Enzyme immunoassay, PCR  Vaccine available Rota = Wheel EM Pix
  • 61.  Spread by contaminated food and water, feces & vomitus – takes <=20 virus particles to cause infection – highly contagious  Tagged the “Cruise line virus” – numerous reported food borne epidemics on land and sea  Leading cause of epidemic gastroenteritis – more virulent GII.4 Sydney since spring 2012 • Fluid loss from vomiting can be debilitating  Disease course usually limited, 24-48 hours  PCR for diagnosis • Cannot be grown in cell culture
  • 63.  CD4 primary receptor site for entry of HIV into the lymphocyte  Reverse transcriptase enzyme converts genomic RNA into DNA  Transmission - sexual, blood and blood product exposure, perinatal  Non infectious complications: • Lymphoma, KS, Anal cell CA, non Hodgkins Lymphoma
  • 64. Antibody EIA with Western Blot confirmation (old way)  Positive tests must be confirmed with a Western blot test  Western blot detects gp160/gp120 (envelope proteins), p 24 (core), and p41(reverse transcriptase)  Must have at least 2 solid bands on Western blot to confirm as a positive result New test - Antigen/antibody combination (4th generation) immunoassay* that detects IgG and IgM HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen to screen for established and acute infection Detects infection earlier (@ 2- 4 weeks Positive patients on either test require additional testing:  HIV viral load quantitation >= 100 copies  Resistance Testing – report subtype  Most isolates in USA type B •Monitor CD4 counts for infection severity
  • 65.  Non-compliant patients or newly diagnosed • Pneumocystis • Cryptococcus neoformans & Histoplasma capsulatum (disseminated) • TB/Mycobacterium avium complex (disseminated) • Microsporidia and Cryptosporidium (Intestinal) • Hepatitis B • Hepatitis C • STD’s – Syphilis, GC, Chlamydia  Syphilis rate high (mucosal contact)
  • 67. Known as the “Three day measles” – German measles Rash, low grade fever, cervical lymphadenopathy Respiratory transmission Congenital rubella – • occurs in a developing fetus of a pregnant women who has contracted Rubella, highest % (50%) in the first trimester pregnancy • Deafness, eye abnormalities, congenital heart disease Diagnosis - Serology in combination with clinical symptoms Live attenuated vaccine (MMR) to prevent
  • 69.  USA outbreak in four corner states (NM,AZ,CO,UT) on Indian reservation in 1993 brought attention to this virus  Source - Urine and secretions of wild field mice • Deer mouse (picture) and cotton rat  Myalgia, headache, cough and respiratory failure  Found in states west of the Mississippi River  Diagnosis by serology  No therapy
  • 70. Smallpox virus (Variola virus) Vaccinia virus
  • 71.  Variola virus – agent of Smallpox  Vaccinia virus - active constituent in the Smallpox vaccine, it is immunologically related to smallpox, • Vaccinia can cause disease in the immune suppressed, which prevents vaccination of this population • Eradication of smallpox (1977)  Disease begins as maculopapular rash and progresses to vesicular rash - • all lesions in same stage of development in one body area – rash moves from central body outward  Category A Bioterrorism agent (can maim or kill)  Requires BSL4 laboratory (self contained lab)  Reported to public health department for investigation
  • 72. Chicken pox – Lesions in different stage of development Smallpox – all lesions same stage of development Chickenpox vs Smallpox lesions
  • 74.  Worldwide in animal populations • Bat and raccoons primary reservoir in US • Dogs in 3rd world countries  Post exposure shots PRIOR to the development of symptoms prevent infection  Rabies is a neurologic disease – classic sympton is salivation, due to paralysis of throat muscles  Detection of viral particles in the brain by Histologic staining known as Negri bodies is diagnostic  Public health department should be contacted to assist with diagnosis
  • 75. Rabies virus particles EM showing the bullet shaped virus Negri bodies – Intracytoplasmic brain biopsy specimen
  • 76.  Rare, degenerative fatal brain disorder  Transmissable spongiform encephalopathies (TSE) name established from the microscopic appearance of brain with infection  Caused by type of protein - prion  Confirmation by brain biopsy  Safety – prevent transmission • Universal Precautions • Use disposable equipment when possible